These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Antibody-Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End? Ray U; Orlowski RZ Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111346 [TBL] [Abstract][Full Text] [Related]
46. Anti-BCMA novel therapies for multiple myeloma. Sammartano V; Franceschini M; Fredducci S; Caroni F; Ciofini S; Pacelli P; Bocchia M; Gozzetti A Cancer Drug Resist; 2023; 6(1):169-181. PubMed ID: 37065871 [TBL] [Abstract][Full Text] [Related]
47. Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives. Shrivastava T; Van Rhee F; Al Hadidi S Onco Targets Ther; 2023; 16():441-464. PubMed ID: 37359353 [TBL] [Abstract][Full Text] [Related]
48. Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma. Chekol Abebe E; Yibeltal Shiferaw M; Tadele Admasu F; Asmamaw Dejenie T Front Immunol; 2022; 13():991092. PubMed ID: 36119032 [TBL] [Abstract][Full Text] [Related]
49. Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth. Sun F; Cheng Y; Wanchai V; Guo W; Mery D; Xu H; Gai D; Siegel E; Bailey C; Ashby C; Al Hadidi S; Schinke C; Thanendrarajan S; Ma Y; Yi Q; Orlowski RZ; Zangari M; van Rhee F; Janz S; Bishop G; Tricot G; Shaughnessy JD; Zhan F Nat Commun; 2024 Jan; 15(1):615. PubMed ID: 38242888 [TBL] [Abstract][Full Text] [Related]
50. Plasma levels of BCMA-positive extracellular vesicles correlate to response and side effects in myeloma patients treated with belantamab-mafodotin. Springer C; Krauter J; Trummer A Oncotarget; 2023 Dec; 14():949-956. PubMed ID: 38039414 [TBL] [Abstract][Full Text] [Related]
52. Idecabtagene vicleucel for relapsed/refractory multiple myeloma: a review of recent advances. Tu W; Xiao Y; Wang Y; Luo R; Chen ZS Drugs Today (Barc); 2022 Mar; 58(3):117-132. PubMed ID: 35274631 [TBL] [Abstract][Full Text] [Related]
53. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis. Yang Q; Li X; Zhang F; Yang Q; Zhou W; Liu J Int J Med Sci; 2021; 18(8):1786-1797. PubMed ID: 33746596 [No Abstract] [Full Text] [Related]
54. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma. Feng D; Sun J Scand J Immunol; 2020 Aug; 92(2):e12910. PubMed ID: 32471019 [TBL] [Abstract][Full Text] [Related]
55. BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma. Fang J; Zhou F Ann Hematol; 2024 Apr; 103(4):1069-1083. PubMed ID: 37704875 [TBL] [Abstract][Full Text] [Related]
56. Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma. Ma T; Shi J; Liu H Ann Hematol; 2019 Apr; 98(4):813-822. PubMed ID: 30693373 [TBL] [Abstract][Full Text] [Related]
57. Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma. Zah E; Nam E; Bhuvan V; Tran U; Ji BY; Gosliner SB; Wang X; Brown CE; Chen YY Nat Commun; 2020 May; 11(1):2283. PubMed ID: 32385241 [TBL] [Abstract][Full Text] [Related]
58. Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma. Fang Y; Hou J Mil Med Res; 2021 Jan; 8(1):9. PubMed ID: 33504363 [TBL] [Abstract][Full Text] [Related]
59. Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma. Anderson LD Future Oncol; 2022 Jan; 18(3):277-289. PubMed ID: 34854741 [TBL] [Abstract][Full Text] [Related]